XOMA Receives Orphan Drug Designation in the European Union for XOMA 358 for Treatment of Congenital Hyperinsulinism
July 20, 2016 09:00 ET
|
XOMA Corporation
XOMA 358 previously secured Orphan Drug Designation from the FDA for the treatment of Congenital Hyperinsulinism (CHI)Phase 2 clinical studies currently enrolling patients with CHI in the United...
XOMA to Present at the Cantor Fitzgerald Healthcare Conference
July 05, 2016 14:05 ET
|
XOMA Corporation
BERKELEY, Calif., July 05, 2016 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today that Dr. Paul Rubin, the...
XOMA to Present at the Jefferies Global Healthcare Conference
June 02, 2016 13:48 ET
|
XOMA Corporation
BERKELEY, Calif., June 02, 2016 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today that John Varian, the...
XOMA Reports First Quarter 2016 Operational Achievements and Financial Results
May 04, 2016 16:01 ET
|
XOMA Corporation
BERKELEY, Calif., May 04, 2016 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced recent operational...
XOMA Reports Fourth Quarter and Full-Year 2015 Financial Results
March 09, 2016 16:01 ET
|
XOMA Corporation
BERKELEY, Calif., March 09, 2016 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today reported the completion of its...
XOMA to Present at the Cowen & Company Health Care Conference
March 02, 2016 13:30 ET
|
XOMA Corporation
BERKELEY, Calif., March 02, 2016 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today Paul Rubin, the Company’s...
XOMA to Announce Fourth Quarter and Full Year 2015 Financial Results and Host Webcast on March 9
February 24, 2016 13:28 ET
|
XOMA Corporation
BERKELEY, Calif., Feb. 24, 2016 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of antibody therapeutics, announced the Company will host a conference...